Navigation Links
Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities

NEW YORK, Dec. 2 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities

Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in hepatitis C virus therapeutics market is on the verge of a major breakthrough. The Hepatitis C Virus (HCV) therapeutics development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages. Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.

These and other market data and trends are presented in "Hepatitis C Virus And Therapeutics: A Global Update of Market Trends & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.




Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3


Pegylated Alpha Interferon Plus Ribavirin - The Standard Therapy 5

Approved Drugs for HCV Combination Therapy 5

Alpha Interferons and Ribavirin are Here to Stay 5

Interferon-based Drugs in Pipeline by Company and Development

Albuferon - Rising Above the Standards 6

Viramidine - Next-Generation Ribavirin Drug 6

High Mutation Rates Keep HCV Elusive 7

Genotype I - Least Responsive and Most Common Variant of HCV 7

Protease Inhibitors (PIs) - Way Above Others 7

Protease Inhibitor Drugs in Pipeline by Company and

Development Stage 8

SCH 900518 - Schering's Next-Generation Protease Inhibitor 8

Telaprevir (VX-950) - The Most Promising Pipeline HCV

Protease Inhibitor 9

Boceprevir - Schering's PI Class Lead Candidate 9

Comparison Between Telaprevir and Boceprevir 10

Telaprevir and Boceprevir - A Comparison 11

Polymerase Inhibitors (PLIs) - Adding More Teeth to HCV Pipeline 11

Viral Polymerases 11

Polymerase Inhibitor Drugs in Pipeline by Company, Category,

and Development Stage 12

R7128 - A Promising PLI Class Drug 12

Development of PLIs Remains a Challenge for HCV Researchers 13

Industry in Search of Novel STAT-C Drugs 13

Specific Antiviral Activity of Select HCV Drug Classes 14

Select NS5A Inhibitors, Entry Inhibitors, and Thiazolides in

Pipeline by Company and Development Stage 14

Researchers Show Continued Appetite for Immunomodulators and

Other Classes 15

Immunomodulators in Pipeline by Company, and Development Stage 15

Adjuvant Therapies to Compete with Mainline Therapies 15

Cyclophilin Analogs and Fibrosis/ Inflammation Inhibitors in

Pipeline by Company 16

Vaccine Development Remains at Low Scale 16

HCV Vaccines in Pipeline by Company, and Development Stage 16

Decisive Factors For Success of New HCV Therapeutics 17

HCV Treatment Costs to Escalate 17

Roche & Schering - Dominant Players in HCVTherapeutics Market 17

HCV Drugs from Roche & Schering 18

Partnerships in R&D Become Order of the Day 18

Select Partnership Deals in HCV DrugDevelopment Programs 19

Market Drivers/Constraints 20

Treatment-Experienced Patients - A Potential Opportunity for

Developers 20

Education Campaigns to Magnify Patient Diagnosis Rates 20

Stigmatization and Discrimination - Major Hurdles for HCV

Treatment 21

Treatment with Current Therapies Plagued by Side Effects 21

Hemolytic Anemia - A Key Side Effect with Ribavirin 21

Epidemiology 21

Quick Facts about HCV Infection 21

Low-Treatment Rates vis-à-vis Patient Population 22

Factors Influencing HCV Treatment Market 23

Drivers 23

Bottle Necks 23


Approved Drugs for HCV Treatment 23

Interferons - The Backbone of HCV Treatment 23

Intron® A 24

Roferon A 24

Infergen 24

PEG-Intron® 24

Pegasys 24

FDA Approval of Interferons for Use as Monotherapy in

Chronic Hepatitis C Treatment 25

Ribavirin - Antiviral Drug for HCV Treatment 25

Rebetol® 25

Copegus 25

Drugs in Pipeline for HCV Treatment 26

Select HCV Drugs Under Pipeline (Phase III/Phase II) by Company 27

Select HCV Drugs Under Pipeline (Phase I) by Company 28

Select HCV Drugs in Pre-Clinical/Research Stage by Company 29

Select HCV Drugs with Cancelled Clinical Studies by Company 30


Hepatitis C Virus 31


United States 31

HCV Infection - Ethnicity 32

African-Americans React Poorly to Treatment 32

Genotype 1 - The Most Prevalent HCV Strain 33

Falling HCV Incidences in the US 33

Canada 33

Australia 34

India 35

Egypt 35

France 36

The Netherlands 36

HCV Infection Prevalence in Risk Groups in the Netherlands 37

Central and Eastern Europe 37

HCV Prevalence Rate Higher in Injection Drug Users 37

Alarming Rates of HIV/HCV Co-Infection 37

Testing and Counseling Structure Poorly Developed 37

Depleted Testing Schemes for Prisoners 38

Scarcity Prevails at Health Care Providers and Governments As

Practical Availability of PEG-IFN Remains Limited 38

Dearth in Political Commitment 38

HCV Diagnostic Tests and Treatment in Select CEE Countries 39

Bulgaria 39

Czech Republic 39

Hungary 39

Romania 40

Russia 40

Ukraine 40

Availability of Testing Protocols for HCV in Select CEE

Countries 41


Three Rivers Acquires Infergen® 42

International Consolidated Cos Takes Over China Gene 42

Hologic Signs Definitive Deal to Acquire Third Wave 42

GlaxoSmithKline Inks Deal to Take Over Genelabs 42

Biolex Signs Deal to Purchase OctoPlus' Stake in Locteron® 43

OraSure and Schering-Plough Form Global Alliance 43

Tacere and Oncolys Sign Licensing Agreement 43

Beckman Wins HCV Diagnostics Rights from Siemens Healthcare 44

Anadys Secures FDA Fast Track Designation for its Lead Drug

Candidate 44

Roche Bags European Commission Approval for Combination Therapy 44

Roche Receives European Commission Approval for Shortened

Hepatitis C Therapy 44

iTherX Establishes Advisory Board for Hepatitis C Advanced

Therapeutics 45

SciClone Terminates Zadaxin® 45

Vertex to Initiate Phase III Trial of Telaprevir 45

Amarillo and CytoPharm to Initiate Phase II Study of Novel

Oral Interferon 45

Biolex Releases Locteron® Phase IIa Trial Results 46

Schering-Plough Releases Details of Boceprevir Phase II Study 46

Progenics Releases Pre-Clinical Results of PRO 206 47

ZymoGenetics Reveals Phase Ib Results of IL-29 47

Phenomix Begins Phase Ia Study of PHX1766 48

Inovio and Tripep Release Additional Interim Results for

ChronVac-C® 48

InterMune Starts Clinical Study of ITMN-191 49

Roche and Associates Commence Clinical Trial of All-Oral Dual

-Antiviral Therapy 49

GlobeImmune Announces Phase II Clinical Trials with GI-5005 50

AstraZeneca Acquires Arrow Therapeutics 50

Cubist Takes Over Illumigen 50

China Medical to Take Over Beijing Bio-Ekon 51

Schering-Plough Collaborates with OraSure 51

Pro-Pharmaceuticals to Collaborate with Digna Biotech 51

Medivir and Tibotec Establish Collaboration Deal 52

VGX Extends Collaboration with University of Pennsylvania 52

Presidio Wins Exclusive License to Novel HCV Technology 52

Roche Inks Licensing Deal with Novartis and Ortho-Clinical 52

Peregrine Opens Subsidiary in China 52

InterMune Completes Production Milestone 53

Arrow Expands Hepatitis C Pipeline 53

Roche Wins Japanese Approval for Combination Therapy 53

Schering-Plough Bags European Commission Approval for

Combination Therapy 53

Abbott Bags FDA Approval for Screening Test 53

Abbott Bags Canadian Approval for Viral Load Tests 54

Phynova Bags FDA Approval for IND Application 54

Worldwide Biotech Bags Chinese FDA Approval for HCV Diagnostic

Tibotec Applies to European Regulator to Initiate Phase I Trials 54

Roche Submits Application for Novel Hepatitis C to with FDA 55

Anadys Discontinues ANA975 55

Cerus Bags NIH Funding for HCV Vaccine Program 55

Human Genome Gets Encouraging Interim Results with Albuferon 55

Intarcia Releases Study Results of Omega Interferon 55

Nautilus Biotech Commences Phase I Study for Belerofon® 56

Migenix Announces Phase II Proof-of-Concept Study Results of

Celgosivir 56

Pharmasset Begins Multiple Dose-Escalating Study of R7128 57

Transgene Commences Phase I Trial of TG4040 57

Debiopharm Releases Phase Ib Results of Debio 025 57

Nabi Biopharmaceuticals Starts Proof-Of- Concept Trial for

Civacir 57

Peregrine Announces Positive Results for Bavituximab 58


Abbott Diagnostics (USA) 59

Achillion Pharmaceuticals, Inc. (USA) 59

Anadys Pharmaceuticals, Inc. (USA) 59

Boehringer Ingelheim GmbH (Germany) 59

Bristol-Myers Squibb Company (USA) 59

F. Hoffmann-La Roche Ltd. (Switzerland) 60

GlaxoSmithKline plc (UK) 60

Hayashibara Biochemical Labs, Inc. (Japan) 60

HemispheRx Biopharma, Inc. (USA) 60

Human Genome Sciences (USA) 60

Idenix Pharmaceuticals, Inc. (USA) 61

Innogenetics NV (Belgium) 61

InterMune, Inc. (USA) 61

Intarcia Therapeutics, Inc. (USA) 61

Medivir AB (Sweden) 61

Merck & Co., Inc. (USA) 62

Novartis AG (Switzerland) 62

Chiron Corporation (USA) 62

Pfizer, Inc. (USA) 62

Schering-Plough Corporation (USA) 62

Tibotec Pharmaceuticals Ltd. (Ireland) 63

Tripep AB (Sweden) 63

Toray Industries, Inc. (Japan) 63

Valeant Pharmaceuticals International (USA) 63

Vertex Pharmaceuticals, Inc. (USA) 63


Table 1: Global Hepatitis C Virus Therapeutics Market:

2007-2015 (Sales in US$ Million)

Table 2: Prevalence and Incidence Rate of HCV Infected

Population by Select Country in the World - 2006

Table 3: Annual Sales of Select Interferons & Ribavirins

offered by Major Players in the Global HCV Therapeutics Market

- 2008 (In US$ Million)

Table 4: HCV Infection in the US: Number of Infected People

for the Year 2008 (in '000s)

Table 5: Percentage Breakdown of Infection Sources by Medium

in the US HCV Market - 2007

Table 6: HCV Prevalence by Genotype in the US - 2005 (In %)

Table 7: Market Shares of HCV Infection Transmission Modes in



To order this report:

Therapy Industry: Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities

More Market Research Report

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):